Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPHAEL: GNSC-001 in Knee Osteoarthritis
NCT07831577Phase 3Not yet recruiting
- Sponsor
- Genascence Corporation
- Start
- Jul 2027
- Primary completion
- Oct 2029
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA) comparing GNSC-001 with Placebo (2 arms). Primary endpoints: Weekly Average of Daily Pain Numeric Rating Scale at 52 weeks, Western Ontario and McMaster Universities Osteoarthritis Index Function Subscale at 52 weeks and 1 more. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
GNSC-001
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07831577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831577.